Selank: the anxiety peptide Russia already uses

Selank is Russia’s answer to a question most of the world quietly gave up on: can you take the edge off anxiety without a benzodiazepine? Russian labs built it, the health ministry registered it, and pharmacies there have sold it for anxiety since 2009. Barely anyone in the West has heard of it. That gap — a drug used daily in one country and treated as a research chemical everywhere else — is the thing to understand first.

The promise underneath it is genuinely interesting. A calm that doesn’t sedate you, doesn’t fog your head, and doesn’t build the dependence a benzo leaves behind. If Selank holds up the way the Russian record hints, that’s a real tool, not a forum rumour. This page is the map of the whole thing. The deep case for the anxiety effect — and exactly how far it goes — lives in the full write-up on Selank and anxiety.

What Selank actually is

Selank is a small peptide: seven amino acids, chained together in a lab. It’s built on tuftsin, an even smaller peptide your own immune system snips off an antibody. Russian chemists took that natural fragment and added a short three-part tail — the same trick they used on semax, its better-known cousin. The tail earns its keep. It takes something that lasts minutes in the body and makes it last hours, and it steers the molecule toward the brain.

So the raw material isn’t exotic. It’s a signal your body already makes, re-engineered to stick around long enough to do something. Nothing here came from nowhere.

What it might do for you

The headline use is anxiety. Russian pharmacology files Selank as an anxiolytic — it appears to turn anxiety down without the sedation or the dependence a benzodiazepine brings. For a man who wants to be steadier under load without dulling the edge that makes him good at his work, that’s about as on-target as an anxiety tool gets. The evidence behind that claim, and its limits, sits in the anxiety deep-dive.

There’s more to the molecule than calm. Because it started life as a tuftsin analog — an immune-signalling peptide — Russian researchers have pushed it in other directions too: better attention and memory on task, and, in animal studies, easing the distress of drug withdrawal. None of that is settled science. But it tells you Selank isn’t a one-trick compound. It’s a small peptide that touches several systems at once.

Where it comes from, and why that matters

Selank’s origin is half the reason it’s worth a look. Tuftsin, the peptide it’s built from, is part of your immune system’s own signalling kit. Russian neuroscience has a long, specific tradition of taking short natural peptides like this and turning them into brain drugs — semax came out of the same programme. Selank is that tradition pointed at anxiety.

The mechanism, as far as the animal work shows, runs through the same calm-signalling chemistry a benzodiazepine leans on: serotonin and GABA. It just reaches them by a different route. In rats, Semenova and colleagues (2009) showed Selank restoring serotonin signalling in brains that had been chemically stripped of it. Different door, same room — a calming effect that doesn’t appear to flip the sedation-and-dependence switch a benzo flips.

How far the proof goes

Here’s the part the forums skip. Almost everything known about Selank in actual people was published in Russian, in study designs Western regulators don’t treat as the final word. The most-cited human comparison — Medvedev and colleagues (2014) — put Selank head-to-head against phenazepam, a benzodiazepine, and reported no significant difference in anxiety relief, with better tolerability: less sedation, no dependence signal.

Read that for exactly what it is. A comparison against another drug, not against a placebo. Open-label, modest numbers, in patients already diagnosed — not healthy men taking it before a hard week. That’s real evidence, and comparative work counts. It just isn’t the modern placebo-controlled trial that would settle the question, and nobody has run one.

The gap isn’t the molecule. It’s the trial. Two decades of Russian clinical use is a serious real-world signal, and it still isn’t the same thing as proof — honesty means holding both of those at once.

Where it stands with regulators

Selank sits entirely outside the FDA’s current peptide review. It’s not on the July 2026 PCAC wave, it’s not on the second wave scheduled before the end of February 2027, and it has never faced a PCAC vote — unlike a handful of peptides that were reviewed and rejected back in 2024. It simply isn’t in the process. What a PCAC review actually decides is a longer story, told in what a PCAC review actually is. In the US today, Selank is a research chemical: no FDA approval, no application on file, despite being a registered medicine in Russia.

Anti-doping is stricter than the printed list looks. Selank isn’t named outright on the WADA prohibited list, but the non-approved-substances category is written broadly enough to catch it. If you get tested, treat it as off-limits. The missing name is not a clearance.

The version worth waiting for

Two things are true at once. The Russian record is real, and on its own it isn’t enough. The mechanism is genuinely interesting, and the trial that would prove it is still unwritten.

What’s missing isn’t the compound. It’s the supervision. Selank’s entire safety case in Russia rests on being prescribed and monitored by a doctor — the exact part the grey market strips out when it ships you a nasal spray from a research-chemical checkout. The version worth having looks nothing like that: a physician who knows your history, a US-licensed pharmacy that makes it to spec, and an assay on the bottle before it reaches you. Wolverine Health is being built to be that version — a legitimate route to a peptide people are currently buying blind. It can’t open until the regulation moves, which is the honest reason it hasn’t. Drop your email below and you’ll hear from us the moment Selank is something a doctor can actually put in your hands.